公开(公告)号：US09957292B2

公开(公告)日：2018-05-01

申请号：US14959714

申请日：2015-12-04

Applicant: Ionis Pharmaceuticals, Inc.

Inventor： Thazha P. Prakash ,  Punit P. Seth ,  Eric E. Swayze ,  Susan M. Freier ,  Mark J. Graham ,  Rosanne M. Crooke

IPC: C07H21/02 ,  C07H21/04 ,  C12N15/113 ,  C07H19/20 ,  C07H15/04

CPC classification number: C07H19/20 ,  C07H15/04 ,  C07H21/02 ,  C07H21/04 ,  C12N15/1136 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/3341 ,  C12N2310/341 ,  C12N2310/346 ,  C12N2310/351 ,  C12N2320/32 ,  C12N2310/3525 ,  C12N2310/3231

Abstract: Provided herein are methods, compounds, and compositions for reducing expression of an ANGPTL3 mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for reducing lipids and/or glucose in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of cardiovascular disease and/or metabolic disease, or a symptom thereof, in an individual in need thereof.

公开(公告)号：US20180111955A1

公开(公告)日：2018-04-26

申请号：US15822616

申请日：2017-11-27

Applicant: The Regents of The University of California ,  National University of Dublin

Inventor： Stefan Oscarson ,  John Vincent Fahy ,  Shaopeng Yuan ,  Stephen Carrington

IPC: C07H15/04 ,  C07H5/04 ,  A61K31/7028 ,  A61K31/70 ,  A61K31/7016 ,  A61K31/702 ,  C07D309/10 ,  C07H13/04

Abstract: There are provided, inter alia, methods for decreasing mucus elasticity or decreasing mucus viscosity in a subject in need thereof, the methods including administering to the subject an effective amount of a thiosaccharide mucolytic agent, and compounds and pharmaceutical compositions useful for the methods.

公开(公告)号：US09868754B2

公开(公告)日：2018-01-16

申请号：US14237795

申请日：2012-08-08

Applicant: Andrea Choe ,  Paul W. Sternberg ,  Frank C. Schroeder ,  Stephan H. Von Reuss

Inventor： Andrea Choe ,  Paul W. Sternberg ,  Frank C. Schroeder ,  Stephan H. Von Reuss

IPC: A61K31/7028 ,  C07H15/04 ,  A01N37/36 ,  A01N63/02 ,  A61K31/454 ,  C07H15/08 ,  C07H15/10 ,  C07H15/18 ,  C07H15/26 ,  A01N43/16 ,  A01N43/38 ,  C07D309/10

CPC classification number: C07H15/04 ,  A01N37/36 ,  A01N43/16 ,  A01N43/38 ,  A01N63/02 ,  A61K31/454 ,  A61K31/7028 ,  C07D309/10 ,  C07H15/08 ,  C07H15/10 ,  C07H15/18 ,  C07H15/26

Abstract: The present invention relates to methods of treating immune disorders and/or inflammation using certain modulator compounds. In one embodiment, the present invention provides a method of treating an immune and inflammatory disorders disorder by administering a composition comprising a therapeutically effective dosage of an ascaroside compound, or a mixture of ascaroside compounds, or a mixture containing at least one ascaroside.

公开(公告)号：US20180002365A1

公开(公告)日：2018-01-04

申请号：US15288486

申请日：2016-10-07

Applicant: Genzyme Corporation

Inventor： Luis Z. AVILA ,  Clark Q. PAN ,  Patrick FINN ,  John HARRAHY ,  Qun ZHOU ,  Yunxiang ZHU ,  Paul A. KONOWICZ ,  Duncan E. PATERSON ,  Andreas PEER ,  Joseph P. KUTZKO ,  Michael R. REARDON ,  James E. STEFANO ,  Xiaoyang ZHENG ,  Robert J. MILLER ,  Lauren YOUNG

IPC: C07H15/04 ,  A61K47/61

Abstract: Provided herein are conjugates comprising a protein and an oligosaccharide of one of Formulae I-VI. Also provided herein are pharmaceutical compositions comprising such conjugates. Further provided herein are methods of treating a lysosomal storage disorder in a mammal by administration of an oligosaccharide-glycoprotein conjugate.

公开(公告)号：US20170253875A1

公开(公告)日：2017-09-07

申请号：US15452423

申请日：2017-03-07

Applicant: Arrowhead Pharmaceuticals, Inc.

Inventor： David B. Rozema ,  Darren H. Wakefield ,  Andrei V. Blokhin ,  Jonathan D. Benson ,  Zhen Li ,  Tao Pei ,  Fred Fleitz

IPC: C12N15/113 ,  A61K31/713 ,  C07H15/04

CPC classification number: C12N15/113 ,  A61K31/713 ,  A61K47/549 ,  C07H15/04 ,  C12N2310/14 ,  C12N2310/317 ,  C12N2310/32 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/351 ,  C12N2310/3515 ,  C12N2310/3521 ,  C12N2310/3533 ,  C12N2310/3525

Abstract: Described are novel targeting ligands that may be linked to compounds, such therapeutic compounds, that are useful in directing the compounds to the target in vivo. The targeting ligands disclosed herein can serve to target expression-inhibiting oligomeric compounds, such as RNAi agents, to liver cells to modulate gene expression. The targeting ligands disclosed herein, when conjugated to an expression-inhibiting oligomeric compound, may be used in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Compositions including the targeting ligands disclosed herein when linked to expression-inhibiting oligomeric compounds are capable of mediating expression of target nucleic acid sequences in liver cells, such as hepatocytes, which may be useful in the treatment of diseases or conditions that respond to inhibition of gene expression or activity in a cell, tissue, or organism.

公开(公告)号：US09717790B2

公开(公告)日：2017-08-01

申请号：US14897601

申请日：2014-06-10

Applicant: Victoria Link Limited

Inventor： Regan James Anderson ,  Benjamin Jason Compton ,  Colin Malcolm Hayman ,  Ian Francis Hermans ,  Karen Anne Johnston ,  David Samuel Larsen ,  Gavin Frank Painter

IPC: A61K39/00 ,  A61K39/39 ,  C07D493/08 ,  C07H15/04 ,  C07H15/26 ,  C07H19/01 ,  A61K31/7028 ,  C07H5/10 ,  C07H15/14 ,  C07H17/02 ,  C07D493/04 ,  A61K31/7056 ,  A61K31/706

CPC classification number: A61K39/39 ,  A61K31/7028 ,  A61K31/7056 ,  A61K31/706 ,  A61K39/0011 ,  A61K2039/55572 ,  A61K2039/55583 ,  C07D493/04 ,  C07D493/08 ,  C07H5/10 ,  C07H15/04 ,  C07H15/14 ,  C07H15/26 ,  C07H17/02 ,  C07H19/01 ,  A61K2300/00

Abstract: The invention relates to sphingoglycolipid analogues which are useful in treating or preventing diseases and conditions such as those relating to infection, atopic disorders, autoimmune diseases or cancer.

公开(公告)号：US20170158728A1

公开(公告)日：2017-06-08

申请号：US15325640

申请日：2015-07-10

Applicant: National Research Council of Canada

Inventor： Dennis M. Whitfield ,  G. Dennis Sprott ,  Lakshmi Krishnan

IPC: C07H15/04 ,  A61K39/00 ,  A61K39/39

CPC classification number: C07H15/04 ,  A61K39/0011 ,  A61K39/39 ,  A61K2039/54 ,  A61K2039/55555 ,  A61K2039/55572 ,  A61K2039/57

Abstract: A synthetic charged glycolipid is described comprising a sulfated saccharide group covalently linked to the tree sn-1 hydroxyl group of the glycerol backbone of an archaeal core lipid via a beta linkage. The synthetic charged glycolipids include compounds of formula I wherein n is 0 or 1; R is hydrogen or hydroxyl; and Y is hydrogen or a sulfate group, at least one Y being a sulfate group; and including pharmaceutically acceptable salts thereof. The sulfated glycolipid produces stable archaeosomes at a mol % ratio of from 100:0 to 30:70 (sulfated glycolipid: uncharged glycolipid) and which induce a protective immune response, including CD8+ and CD4+ T cell responses. Archaeosomes comprising the sulfated glycolipids described have desirable adjuvant properties, particularly when mixed with uncharged glycolipid at a mol % ratio of about 50:50.

公开(公告)号：US20170152279A9

公开(公告)日：2017-06-01

申请号：US14646808

申请日：2013-11-28

Applicant: VICTORIA LINK LIMITED ,  UNIVERSITY OF LIVERPOOL

Inventor： Peter Charles Tyler ,  Olga Vladimirovna Zubkova ,  Jeremy E. Turnbull

IPC: C07H15/08 ,  C07H15/04

CPC classification number: C07H15/08 ,  C07H15/04

Abstract: The invention relates to dendritic compounds, the use of these compounds as pharmaceuticals, pharmaceutical compositions containing the compounds, processes for preparing the compounds, and methods of treating diseases or conditions in which it is desirable to inhibit β-secretase.

公开(公告)号：US20170119875A1

公开(公告)日：2017-05-04

申请号：US15316124

申请日：2015-06-05

Applicant: Regan James Anderson ,  Benjamin Jason Compton ,  Colin Malcolm Hayman ,  Ian Francis Hermans ,  Karen Anne Johnston ,  Gavin Frank Painter

Inventor： Regan James Anderson ,  Benjamin Jason Compton ,  Colin Malcolm Hayman ,  Ian Francis Hermans ,  Karen Anne Johnston ,  Gavin Frank Painter

IPC: A61K39/385 ,  A61K39/39 ,  A61K39/00 ,  C07H15/04 ,  C07H15/18

CPC classification number: A61K39/385 ,  A61K39/0011 ,  A61K39/39 ,  A61K47/542 ,  A61K47/549 ,  A61K47/65 ,  A61K2039/55511 ,  A61K2039/60 ,  C07H15/04 ,  C07H15/06 ,  C07H15/18 ,  C07K9/001

Abstract: The invention relates to amino sphingoglycolipid analogues and peptide derivatives thereof, compositions comprising these compounds and methods of treating or preventing diseases or conditions using such compounds, especially diseases or conditions relating to cancer, infection, atopic disorders, autoimmune disease or diabetes.

公开(公告)号：US20170066794A1

公开(公告)日：2017-03-09

申请号：US15119880

申请日：2015-02-24

Applicant: MSD WELLCOME TRUST HILLEMAN LABORATORIES PVT. LTD.

Inventor： Davinder GILL ,  Kishore HARALE ,  Manoj Kumar CHHIKARA

IPC: C07H15/04 ,  C07H1/00 ,  C07H1/02

CPC classification number: C07H15/04 ,  C07H1/00 ,  C07H1/02 ,  C07H11/04 ,  C07H15/12 ,  C08B37/0009

Abstract: The present invention relates to synthesis of novel higher oligomers and process of preparing the same. In particular the present invention relates to the chemical synthesis of oligomers of Neisseria meningitidis serogroup X (‘hereinafter Men-X), more particularly tetramer. The present invention provides Men-X capsular oligomers obtained from synthetic pathway using purified saccharides of specific chain length and provides said novel oligomers as candidates for the development of conjugate vaccine against bacterial meningitis caused due to Men-X infections.

Abstract translation: 本发明涉及新型高级寡聚体的合成及其制备方法。 特别地，本发明涉及脑膜炎奈瑟氏球菌血清群X（以下称为Men-X），更特别是四聚体的低聚物的化学合成。 本发明提供使用纯化的特异链长度的糖的合成途径获得的Men-X荚膜寡聚体，并提供所述新型低聚物作为针对由于Men-X感染引起的针对细菌性脑膜炎的结合疫苗的候选物。